Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2017, Pages 584-591

  Katsube, Takayuki ^a   Echols, Roger ^a   Arjona Ferreira, Juan Camilo ^a   Krenz, Heidi K ^a   Berg, Jolene Kay ^b   Galloway, Christopher ^c  

^a SHIONOGI AND CO LTD   (Japan)

^b DAVITA CLINICAL RESEARCH   (United States)

^c DaVita Inc   (United States)

Author keywords

cefiderocol; cephalosporin; hemodialysis; pharmacokinetics; renal impairment

Indexed keywords

CEFIDEROCOL; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DIZZINESS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; GOUT; GRAM NEGATIVE INFECTION; HEADACHE; HEMODIALYSIS; HOT FLUSH; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY DYSFUNCTION; KLEBSIELLA PNEUMONIAE; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NONHUMAN; OPEN STUDY; PARESTHESIA; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PLASMA CONCENTRATION-TIME CURVE; POLYURIA; PSEUDOMONAS AERUGINOSA; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; WOUND COMPLICATION; BLOOD; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; HALF LIFE TIME; KIDNEY FAILURE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; URINE;

ADULT; AGED; CEPHALOSPORINS; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 85005784390     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.841     Document Type: Article

References (20)

1. Gorska A, Sloderbach A, Marszaff MP. Siderophore-drug complexes: potential medicinal applications of the “Trojan horse” strategy. Trends Pharmacol Sci 2014;35(9):442–449.
2. Ito A, Kohira N, Bouchillon SK, et al. In vitro antimicrobial activity of S-649266, a catechol substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016;71(3):670–677.
3. Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2015;60(2):729–734.
4. Ito A, Toba S, Nishikawa T, et al. S-649266, a novel siderophore cephalosporin: binding affinity to PBP and in vitro bactericidal activity. Presented at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2015); April 25-28, 2015; Copenhagen. Poster P0250.
5. Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. A novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014); September 5-9, 2014; Washington, DC. Poster F-1558.
6. Shimada J, Saisho Y, Katsube T, White S, Fukase H. S-649266, a novel siderophore cephalosporin for Gram negative bacterial infections: pharmacokinetics, safety and tolerability in healthy subjects. Presented at 54th Interscience Conference on Antimicrobial Agents Chemotherapy (ICAAC 2014); September 5-9, 2014; Washington, DC. Poster F-1564.
7. Federal Drug Administration. Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. Fed Register. 2010;75(155):13562–13563.
8. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254.
9. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
10. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther. 1990;48(3):268–276.
11. Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa [published online ahead of print 2016]. Antimicrob Agents Chemother. In press. doi:10.1128/AAC.01405-16.
12. Tillotson GS. Trojan horse antibiotics—a novel way to circumvent Gram-negative bacterial resistance? Infect Dis Res Treatment. 2016;9:45–52.
13. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22(1-2):89–96.
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–12.
15. Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. A novel siderophore cephalosporin: V. Pharmacodynamic assessment in murine thigh infection models. Presented at 54th Interscience Conference on Antimicrobial Agents Chemotherapy (ICAAC 2014); September 5-9, 2014; Washington, DC. Poster F-1559.
16. Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. A novel siderophore cephalosporin: VI. Magnitude of PK/PD parameter required for efficacy in murine lung infection model. Presented at 54th Interscience Conference on Antimicrobial Agents Chemotherapy (ICAAC 2014); September 5-9, 2014; Washington, DC. Poster F-1560.
17. Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. 2014. A novel siderophore cephalosporin: VII. Magnitude of PK/PD parameter required for efficacy in murine thigh infection model. Presented at 54th Interscience Conference on Antimicrobial Agents Chemotherapy (ICAAC 2014); September 5-9, 2014; Washington, DC. Poster F-1561.
18. Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand Suppl. 1983;305:7–11.
19. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(suppl 1):S42–S50.
20. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–871.